Title: ANTI-AGING COMPOSITION CONTAINING RESVERATROL AND METHOD OF ADMINISTRATION

Abstract: Formulations and methods of treatment and putative prevention for aging (anti-aging composition) and for diseases or conditions of all reactive oxygen species-dependent illnesses, such as Alzheimer's disease, Parkinson's disease, diabetes mellitus, cardiovascular disease, cancer, hepatitis, and disorders associated with estrogen deficiencies including osteoporosis and breast cancer and for improving athletic performance of humans include resveratrol and two (2) or more of the following features or additional active ingredients: (1) slow release formulation of resveratrol; (2) pterostilbene; (3) quercetin; (4) fisetin, and (5) naringenin. Slow release is defined for the purposes of the present invention as releasing 95% of the active agent or agents in eight (8) hours through normal human gastrointestinal absorption.
INTERNATIONAL SEARCH REPORT

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61K31/05 A61K31/353

According to International Patent Classification (IPC) or to both national classification and IPC.

B. FIELDS SEARCHED
Minimum documentation searched (classification system followed by classification symbols)
A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic database consulted during the international search (names of data bases and, where practical, search terms used)
EPO-Internal, WPI Data, CHEMABS Data, BIOSIS, EMBASE

C. DOCUMENTS CONSIDERED TO BE RELEVANT

<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
<tbody>
<tr>
<td>X</td>
<td>CN 101 015 350 A (Nanjing Potomac Beauty &amp; Health [CN]) 15 August 2007 (2007-08-15)</td>
<td>1-6, 11-14, 19 see WPI abstract</td>
</tr>
</tbody>
</table>

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:
  A*: document defining the general state of the art which is not considered to be of particular relevance
  E*: earlier document but published on or after the international filing date
  L*: document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
  O*: document referring to an oral disclosure, use, exhibition or other means
  P*: document published prior to the international filing date but later than the priority date claimed
  T*: document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
  X*: document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
  Y*: document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
  S*: document member of the same patent family

Date of the actual completion of the international search: 23 April 2009
Date of mailing of the international search report: 31/07/2009

Name and mailing address of the ISA:
European Patent Office, P.B. 5818 Patentlaan 2 NL-2280 HV Rivierenhoek Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016

Authorized officer:
Economou, Dimi trios

Form PCT/ISA/210 (second sheet) (April 2005)
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with Indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No</th>
</tr>
</thead>
</table>
| X        | EP 1 782 802 A (UNIV VALENCIA [ES])  
page 2, line 10 – line 38  
page 4, line 40 – page 5, line 14  
page 9, line 3 - line 17  
figure 2 | 1-6, 11-14,19 |
paragraphs [0004], [0009], [0099], [0298], [0301], [0303] - [0306]  
paragraphs [0315] - [0338]  
paragraphs [0345] - [0348]  
the whole document | 1-6, 11-14,19 |
| X        | CANDELARIO-JALIL EDUARDO ET AL:  
"Resveratrol potently reduces prostaglandin E2 production and free radical formation in lipopolysaccharide-activated primary rat microglia"  
10 October 2007 (2007-10-10), JOURNAL OF NEUROINFLAMMATION, BIOMEDCENTRAL LTD., LONDON, GB, PAGE(S) 25 , XP021037912  
ISSN: 1742-2094  
abstract  
see "Background" page 6  
see "Discussion"  
see "Conclusion" | 1-6, 11-14,19 |
| X        | LU KWOK TUNG ET AL.:  
"Neuroprotective Effects of Resveratrol on Cerebral Ischemia-Induced Neuron Loss Mediated by Free Radical Scavenging and Cerebral Blood Flow Elevation"  
USA  
the whole document  
abstract  
page 3126, left-hand column - page 3127, left-hand column, line 2  
page 3129, left-hand column, last paragraph - page 3131, left-hand column, line 21 | 1-6, 11-14,19 |
<table>
<thead>
<tr>
<th>Category</th>
<th>Citation of document, with indication, where appropriate, of the relevant passages</th>
<th>Relevant to claim No.</th>
</tr>
</thead>
</table>
INTERNATIONAL SEARCH REPORT

Box No. II  Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos. because they relate to subject matter not required to be searched by this Authority, namely

2. ☐ Claims Nos. because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful internal search can be carried out, specifically

☐ Claims Nos. because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a)

Box No. III  Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple Inventions in this international application, as follows:

see additional sheet

1 ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2 ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of additional fees.

3 ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.

4 ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims, it is covered by claims Nos.

see annex

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee

☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation

☐ No protest accompanied the payment of additional search fees
This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-6 (all part.), 11-14 (all part.), 19 (part.)
   Slow release compositions comprising resveratrol and pterostilbene and optionally an additional compound selected from quercetin, naringenin or fisetin and therapeutic methods.

2. claims: 1-6 (all part.), 11-14 (all part.), 19 (part.)
   Slow release compositions comprising resveratrol and quercetin and optionally an additional compound selected from pterostilbene, naringenin or fisetin and therapeutic methods.

3. claims: 1-6 (all part.), 11-14 (all part.), 19 (part.)
   Slow release compositions comprising resveratrol and naringenin and optionally an additional compound selected from pterostilbene, quercetin or fisetin and therapeutic methods.

4. claims: 1-6 (all part.), 11-14 (all part.), 19 (part.)
   Slow release compositions comprising resveratrol and fisetin and optionally an additional compound selected from pterostilbene, quercetin or naringenin and therapeutic methods.

5. claims: 7-10 (all part.), 15-18 (all part.), 20 (part.)
   Immediate release compositions comprising resveratrol and pterostilbene and optionally an additional compound selected from quercetin, naringenin or fisetin and therapeutic methods.

6. claims: 7-10 (all part.), 15-18 (all part.), 20 (part.)
   Immediate release compositions comprising resveratrol and quercetin and optionally an additional compound selected from pterostilbene, naringenin or fisetin and therapeutic methods.

7. claims: 7-10 (all part.), 15-18 (all part.), 20 (part.)
Immediate release compositions comprising resveratrol and naringenin and optionally an additional compound selected from quercetin, pterostilbene or fisetin and therapeutic methods.

8. claims: 7-10(all part.), 15-18 (all part.), 20(part.)

Immediate release compositions comprising resveratrol and fisetin and optionally an additional compound selected from pterostilbene, quercetinm or naringenin and therapeutic methods.
<table>
<thead>
<tr>
<th>Patent document cited in search report</th>
<th>Publication date</th>
<th>Patent family member(s)</th>
<th>Publication date</th>
</tr>
</thead>
<tbody>
<tr>
<td>CN 101015350 A</td>
<td>15-08-2007</td>
<td>NONE</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1735004 A1</td>
<td>27-12-2006</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2007532543 T</td>
<td>15-11-2007</td>
</tr>
<tr>
<td></td>
<td></td>
<td>KR 20070041427 A</td>
<td>18-04-2007</td>
</tr>
<tr>
<td>WO 2005065667 A</td>
<td>21-07-2005</td>
<td>AU 2004312072 A1</td>
<td>21-07-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CA 2548671 A1</td>
<td>21-07-2005</td>
</tr>
<tr>
<td></td>
<td></td>
<td>EP 1708689 A2</td>
<td>11-10-2006</td>
</tr>
<tr>
<td></td>
<td></td>
<td>JP 2007527418 T</td>
<td>27-09-2007</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DK 1782802 T3</td>
<td>06-07-2009</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 2323721 T3</td>
<td>23-07-2009</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ES 2246165 A1</td>
<td>01-02-2006</td>
</tr>
<tr>
<td></td>
<td></td>
<td>WO 2006024685 A1</td>
<td>09-03-2006</td>
</tr>
<tr>
<td>US 2006084135 A</td>
<td>20-04-2006</td>
<td>NONE</td>
<td></td>
</tr>
</tbody>
</table>